Edition:
United Kingdom

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

368.15INR
11:28am BST
Change (% chg)

Rs8.25 (+2.29%)
Prev Close
Rs359.90
Open
Rs361.90
Day's High
Rs370.40
Day's Low
Rs353.50
Volume
1,190,796
Avg. Vol
1,096,721
52-wk High
Rs711.90
52-wk Low
Rs353.50

Summary

Name Age Since Current Position

Glenn Saldanha

49 2011 Executive Chairman of the Board, Chief Executive Officer, Managing Director

V. S. Mani

2018 Global Chief Financial Officer, Executive Director

Harish Kuber

2017 Compliance Officer, Company Secretary

Cherylann Pinto

Director - Corporate Affairs, Executive Director

Rajesh Desai

52 2017 Non-Executive Director

Blanche Saldanha

2005 Non-Executive Director

Sona Ramasastry

2019 Additional Independent Director

Sridhar Gorthi

47 2005 Non-Executive Independent Director

Devendra Mehta

81 2009 Non-Executive Independent Director

Bernard Munos

2012 Non-Executive Independent Director

Julio Ribeiro

2003 Non-Executive Independent Director

Milind Sarwate

58 2015 Non-Executive Independent Director

Brian Tempest

2012 Non-Executive Independent Director

Biographies

Name Description

Glenn Saldanha

Mr. Glenn Mario Saldanha serves as Executive Chairman of the Board, Chief Executive Officer, Managing Director of Glenmark Pharmaceuticals Ltd. Mr. Saldanha joined Glenmark in 1998 as Director and took over as Managing Director & CEO in 2000. He transformed Glenmark into a truly global organisation with revenue over a billion dollar. Under his leadership, Glenmark has evolved from an Indian branded generics business into a research-driven and innovation-led organisation. Mr. Saldanha’s vision is to discover, develop and take to market India's first innovative drug for the entire world.

V. S. Mani

Mr. V. S. Mani serves as Global Chief Financial Officer, Executive Director of the Company. Mr. Mani leads the organisation’s worldwide finance operations and secretarial function, including global accounting, financial reporting, tax and treasury. He has over 25 years of rich industry experience across treasury, taxation, accounting, financial planning & analysis, secretarial, legal, audits, risk management and investor relations. Prior to joining Glenmark in 2017, he was the President Finance at the Bhartiya Group. He has also held the position of the Chief Financial Officer at Cipla.

Harish Kuber

Cherylann Pinto

Mrs. Cherylann (Cheryl) Pinto is Director - Corporate Affairs, Executive Director of the Company. Mrs. Pinto is the Director of Corporate Affairs at Glenmark since October 1999 and is an executive member of the Board. With over 28 years of experience in the pharmaceutical field, she currently heads the Company’s Corporate Communications, Corporate Affairs, IT, Admin, HR and CSR functions. She had set up a pharmaceutical company where she served as the Managing Director from 1989 to 1999 before joining Glenmark.

Rajesh Desai

Mr. Rajesh V. Desai serves as Non-Executive Director of the Company. He has over 34 years of work experience and was the Executive Director and Chief Financial Officer of Glenmark till 2016. He led the Finance, Legal and IT functions and with his strong Finance background, he contributed significantly to the growth story of Glenmark.

Blanche Saldanha

Mrs. Blanche E. Saldanha serves as Non-Executive Director of Glenmark Pharmaceuticals Ltd. Mrs. Saldanha is a Non-Executive Director and a member of the promoter group of Glenmark. Prior to this, she was the Director for exports and managed Glenmark’s international operations from 1982 to 2005. During her 23-year tenure with the organisation, she was responsible for developing and growing the Company’s export business.

Sona Ramasastry

Sridhar Gorthi

Mr. Sridhar Gorthi serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Mr. Gorthi is a partner in the Mumbai office of Trilegal and his areas of expertise include M&A, joint ventures, private equity and venture capital. He has been actively involved in several high-profile cross-border transactions. Apart from representing several international clients on M&A in India, he has also advised Indian companies about outbound M&A transactions in jurisdiction such as the UK, the US, South Africa, Argentina, Indonesia and Sri Lanka.

Devendra Mehta

Shri. Devendra Raj Mehta serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Mr. Mehta was a civil servant for almost four decades and has experience in administration and management of public affairs. He joined the IAS in 1961 and has held positions in the Government of Rajasthan and in the Government of India. He has served as the Chairman of SEBI, the Deputy Governor of the RBI and the Director General of Foreign Trade, Ministry of Commerce, Government of India.

Bernard Munos

Mr. Bernard Munos serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Mr. Munos advises organisations on being better innovators. He serves on the advisory council of the National Centre for Advancing Translational Sciences (NCATS), is a member of the National Academy of Medicine’s Forum on Drug R&D and Translation and is an advisor to the journal, Science Translational Medicine. His research on pharmaceutical innovation has been published in Nature and Science, as well as profiled by Forbes magazine.

Julio Ribeiro

Mr. Julio F. Ribeiro serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Mr. Ribeiro is a retired Indian police officer and civil servant and has held increasingly responsible positions during his career. Some of the noteworthy positions include the Commissioner of Police, Mumbai; Special Secretary to the Government of India, Ministry of Home Affairs; Director General of Police, Punjab; Advisor to the Governor of Punjab, and Ambassador of India to Romania. He currently serves as the Director of VVF Ltd.

Milind Sarwate

Shri. Milind Shripad Sarwate serves as Non-Executive Independent Director of the Company. Mr. Sarwate is the Founder and CEO of Increate Value Advisors LLP, a firm that facilitates organisations and individuals to discover, develop and deliver business and social value. He has over 32 years of experience in Finance, HR and Strategy in groups such as Marico and Godrej.

Brian Tempest

Dr. Brian William Tempest serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Dr. Tempest has been working with the pharmaceutical industry for the last four decades and has managed healthcare businesses in North America, South America, Europe, Africa, the Middle East, Australasia, China, Japan and India. He is the editor of the Journal of Generic Medicines. He is also a Non-Executive Director on the Governance Board of the United Nations Patent Pool.

Basic Compensation

Name Fiscal Year Total

Glenn Saldanha

161,620,000

V. S. Mani

21,140,000

Harish Kuber

2,750,000

Cherylann Pinto

42,940,000

Rajesh Desai

1,200,000

Blanche Saldanha

400,000

Sona Ramasastry

--

Sridhar Gorthi

1,600,000

Devendra Mehta

1,600,000

Bernard Munos

400,000

Julio Ribeiro

1,600,000

Milind Sarwate

1,600,000

Brian Tempest

400,000
As Of  31 Mar 2018